Current cornerstone treatments for metastatic melanoma include immune checkpoint modulators, such as LAG3 inhibitors, pembrolizumab, nivolumab, and ipilimumab targeting CTLA-4, and PDL1 [9,15]. The gene discussed is CTLA4; the disease is metastatic melanoma.